R&D | December 30, 2025
Chennai's VS Hospitals introduce cutting-edge brain therapy with TMS
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
Subscribe To Our Newsletter & Stay Updated
